Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436408 · ClinicalTrials.gov registry record · Phase 4
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
A Phase 4 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT02436408 is a Phase 4 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 35 participants.
The verdict
NCT02436408, a Phase 4 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
Basal cell carcinoma (BCCA) is the most common human cancer, and frequently affects facial structures. While rarely fatal, facial BCCA can be disfiguring and expensive to treat. Vismodegib is a small molecule inhibitor of SMO developed for the treatment of tumors in which the Hh signaling pathway appears to contribute to the development and maintenance of tumorigenesis. Vismodegib was recently approved by the Food and Drug Administration (FDA) for treatment of metastatic and locally advanced BCCA. Recent reports have suggested that vismodegib treatment for orbital BCCA may facilitate eye preservation even if surgery is eventually required In order to assess the potential of vismodegib to improve the ophthalmic outcomes following treatment for orbital and/or periocular BCCA, this study will follow patients with globe-threatening orbital and lacrimal-threatening periocular BCCA who are being treated with vismodegib as standard of care. Patients with tumors that do not respond to treatment with Vismodegib, and those who have a good response but poor tolerance of Vismodegib, will be offered surgical excision of the tumor. Patients with a good response and good tolerance of Vismodegib may continue the treatment as long as clinically indicated.
Interventions
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-07-15 |
| Est. Completion | 2020-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02436408
The ClinicalTrials.gov registry entry for NCT02436408 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vismodegib is the first listed.
NCT02436408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02436408 about?
NCT02436408 is a clinical study titled "VISmodegib for ORbital and Periocular Basal Cell Carcinoma". Basal cell carcinoma (BCCA) is the most common human cancer, and frequently affects facial structures. While rarely fatal, facial BCCA can be disfiguring and expensive to treat. Vismodegib is a small molecule inhibitor of SMO developed for the treatment of tumors in which the Hh signaling pathway a...
What is the current status of trial NCT02436408?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2015-07-15. Estimated completion is 2020-09.
What interventions are being tested in trial NCT02436408?
The interventions under investigation include: Vismodegib (DRUG).
Who is sponsoring clinical trial NCT02436408?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.